Michiel Strijbos, MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses the increasing importance of the de-escalation of chemotherapy to maintain patients’ quality of life whilst maintaining good survival outcomes. The European Society for Medical Oncology (ESMO) has generated a framework on how to approach de-escalation, including strategies such as biomarkers and imaging. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
